• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    High Drug Loading Amorphous Solid Dispersions

    Parenteral Drug Delivery Trends

    Selecting the Right Outsourcing Model for Emerging Biotech

    Inhaled Drug Delivery Technology

    The Future of Biologics: Accelerating Production, Reducing Costs
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    J&J’s Single-Dose COVID-19 Vax Issued EUA

    Icon to Acquire PRA Health Sciences

    Phlow Corp. and USP Form Alliance

    BMS Expands Cell Therapy Manufacturing Capabilities

    Novo Nordisk Invests $80M in Tablet Production
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    BMS Expands Cell Therapy Manufacturing Capabilities

    Novo Nordisk Invests $80M in Tablet Production

    Arcline Investment Acquires ChargePoint Technology

    Solid Dose Market Trends

    CatSci Opens New Site in UK
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Reshaping the Pharmaceutical Supply Chain

    Covectra Introduces Next-Gen Serialization Solution

    Bormioli Opens New Glass Research Center

    Centrient Pharmaceuticals to Acquire Astral SteriTech

    Seasonal Vaccine Manufacturing
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Icon to Acquire PRA Health Sciences

    BMS Expands Cell Therapy Manufacturing Capabilities

    Ashfield Engage, Popit Form Digital Monitoring Collaboration

    AMRI Contributes to Efforts to Increase COVID-19 Vax Supply

    CatSci Opens New Site in UK
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Guide to Maintaining Validation of Older Facilities: Why, When and How

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Cytovance Biologics

    Baxter BioPharma Solutions

    Flow Sciences

    PCI Pharma Services

    Aphena Pharma Solutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Alcami

    Aphena Pharma Solutions

    Syngene

    Reed-Lane

    Flow Sciences
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Pharma Beat

    ‘Smart’ Heparin Delivery Could Self-Modulate

    A group of researchers have spent the past two years investigating self-controlling dosing and monitoring systems

    Related CONTENT
    • Injectables Firms Expand Capacity
    • Bye-Bye China?
    • Dow Offers New Technology to Solve Pharma Challenges
    • Tackling TB Resistance
    • Espero Pharma and Armetheon Merge
    Adele Graham-King, Contributing Editor01.26.17
    Anticoagulants have had an amazing development pathway since the discovery of heparin in 1916 by Jay McLean at John Hopkins University and their impact on patients’ lives has been nothing other than dramatic. Over the decades the development of these anti-clot medicines has evolved rapidly alongside expanding the clinical areas of usage accompanied by approved licensing.

    Used for various medical conditions including treatment and prevention of deep vein thrombosis (DVT), treatment and prevention of pulmonary embolism (PE), myocardial infarction (MI), unstable angina, atrial fibrillation (AF), occlusive stroke, and hemo-filtration, their efficacy is undisputable and the morbidity and mortality of patients has massively improved over the past 50 years.

    Historically all anticoagulants—apart from warfarin—have been delivered via subcutaneous injections until the arrival of the novel oral anticoagulants (NOACs) in the late 2000s. Both heparin and low-molecular-weight-heparins (LMWHs) are injectable subcutaneously, which will always create issues with regards to patient compliance and can carry the risk of hematoma and more seriously, heparin-induced thrombocytopenia (HIT). While warfarin is an oral alternative it takes time to achieve the required level of anticoagulation and also requires regular monitoring of INR (international normalized ratio). For these reasons warfarin isn’t used in acute management situations but for long-term anticoagulation.

    The arrival of the NOACs—dabigatran, rivaroxaban, apixaban and edoxaban—has seen great efficacy in anticoagulation without the issues of delivery route, but they aren’t without their potential problems and the cost implications. NOACs have a rapid onset and a relatively short half-life and are therefore suitable to be used in the acute setting. However, they are costly and have no effective approved antidote other than for dabigatran. Given that, they require no monitoring unlike warfarin, which can often sway the finances in favor of the NOACs. However, whichever way you look at it, all the anticoagulant options are standardized dosing regimens and the lack of monitoring can lead to inadequate or overzealous activity. The delivery of anticoagulation can be anything but precise, but this may be about to change.

    Considering that standard heparin has been available “cheap as chips” for years, if an effective delivery and “live” monitoring system could be created without the need for invasive drug delivery and additional monitoring, this has the potential to not only improve the anticoagulation control but also reduce the cost of medication compared to other newer agents. The risks associated with uncontrolled heparinization are hefty at either end of the scale. Too much and there is a risk of hemorrhage and too little and there is a risk of clotting. As with any disease management, tight control with minimum effort will always result in the best outcomes.

    A group of researchers from North Carolina State University and the University of North Carolina at Chapel Hill have spent the past two years investigating the options for such an innovative self-controlling dosing and monitoring system for anticoagulation, and recently released preliminary results of their developments. After assessing alternatives the scientists have worked to develop a skin patch, which has the potential to not only deliver, but also monitor and modulate delivery of heparin.

    The patch, which has been developed to incorporate microneedles consisting of hyaluronic acid (HA) and loaded with heparin, has been modified such that the HA is able to detect differing levels of thrombin. Thrombin is involved in the coagulation cascade by converting fibrinogen into fibrin, and increasing coagulative activity in the blood. Although naturally and physiologically involved in the clotting process, increased levels of thrombin are associated with pathological states and can be controlled by the anti-Xa activity of pharmacological agents such as heparin and LMWH, which are historically delivered subcutaneously.

    When applied to the skin tissue the microneedles pierce the cutaneous layers and are able to detect alterations in the level of thrombin enzymes. Elevated levels of thrombin cause the HA to release increased amounts of heparin, and a reduction in the levels has the opposite effect, creating a closed loop system for delivery of the antithrombotic without additional monitoring of dose and maintaining thrombin levels within normal physiological limits.

    In animal-based research studies the results have been impressive. Using a mouse model the animals were injected with what would potentially be a lethal dose of thrombin if left untreated. The first experiment involved giving either a heparin injection, applying the HA-heparin patch to the skin or no treatment 10 minutes prior to the injection of thrombin. Fifteen minutes after the thrombin injection all treated mice (heparin on HA-heparin patch) animals survived, whereas all untreated specimens died.

    In a second experiment the thrombin injection was applied 6 hours following treatment and 80% of the heparin treated mice died whereas all the animals with the HA-heparin mice survived. The indications are that the HA-heparin patch has maintained anticoagulative activity for a prolonged period of time sustaining its efficacy.

    Heparin is a widely used medicine, which has an important place in management of coagulation. If an effective delivery mechanism can be created to decrease the discomfort of injections and reduce the necessity for blood monitoring this will be a really progressive step.

    If at the same time it can push the cost of medication in the right direction the use of heparin could be completely rejuvenated. Although only proven in animal models at the moment the research group is sourcing funding to take the “smart” patch into pre-clinical testing. There is the potential to be able to adapt dose, modify delivery period and personalize the medicine. We’re used to seeing patches for delivering HRT and nicotine, but being able to introduce a monitoring device at the same time would be a real bonus.


    Adele Graham-King
    Contributing Editor
    Adele is a design consultant who works in product development for medical and healthcare applications. Her background is in pharma, and she has a degree in applied physiology.
    Related Searches
    • Drug Delivery
    • Drug Development
    • R&D
    Suggested For You
    Injectables Firms Expand Capacity Injectables Firms Expand Capacity
    Bye-Bye China? Bye-Bye China?
    Dow Offers New Technology to Solve Pharma Challenges Dow Offers New Technology to Solve Pharma Challenges
    Tackling TB Resistance Tackling TB Resistance
    Espero Pharma and Armetheon Merge Espero Pharma and Armetheon Merge
    Biomanufacturing Trends and Outlook 2017: Where Is It All Going? Biomanufacturing Trends and Outlook 2017: Where Is It All Going?
    Plasticell, Kings College Partner on Blood Platelet Substitute     Plasticell, Kings College Partner on Blood Platelet Substitute    
    Could Nuts Ward Off Cancer? Could Nuts Ward Off Cancer?
    MilliporeSigma Launches Commercial Service to Predict DNA Damage MilliporeSigma Launches Commercial Service to Predict DNA Damage
    Trends in Pharma Analysis Trends in Pharma Analysis
    The Trials and Tribulations  of Male Contraception The Trials and Tribulations of Male Contraception
    Oral Solid Dose and the Psychology of Appearance Oral Solid Dose and the Psychology of Appearance
    API Makers Speed Expansion API Makers Speed Expansion
    Enamine, Actelion Expand Drug Discovery Collaboration Enamine, Actelion Expand Drug Discovery Collaboration
    MilliporeSigma, Acticor Biotech Form Pact MilliporeSigma, Acticor Biotech Form Pact

    Related Pharma Beat

    • Drug Development

      NSAIDs – Friend or Foe?

      Although widely used for years, NSAIDs have side effects that could eventually change their OTC status
      Adele Graham-King, Contributing Editor 06.06.17

    • Drug Development | Drug Discovery
      Tackling TB Resistance

      Tackling TB Resistance

      The TB Alliance is partnering with universities, government agencies, public agencies and a small number of pharma compani
      Adele Graham-King, Contributing Editor 05.09.17

    • Drug Development

      Could Nuts Ward Off Cancer?

      Recent research looks into the anti-cancer properties of various nuts
      Adele Graham-King, Contributing Editor 04.03.17


    • Drug Development | Drug Discovery | R&D

      Is Nicotine Such a ‘Bad Boy’?

      Investigating this controversial compound’s potential health benefits
      Adele Graham-King, Contributing Editor 11.09.16

    • Drug Development | Drug Discovery | R&D

      Blackberry Wine: Could it Help Your Diabetes?

      Recent research points towards the positive impact ‘berry wine’ might have on diabetes
      Adele Graham-King, Contributing Editor 10.11.16

    • Chemistry | Drug Development
      Anyone Fancy a Beer?

      Anyone Fancy a Beer?

      The centuries-old brew continues to be investigated for its medicinal properties
      Adele Graham-King, Contributing Editor 05.05.16


    • Drug Development

      Chipping Away at the Old Cancer Block

      Advances in cancer treatment continue to march towards finding a cure
      Adele Graham-King, Contributing Editor 04.05.16

    • Clinical Trials | Drug Development

      The 3D Printed Pill

      It’s the future…or is it?
      Adele Graham-King, Contributing Editor 01.28.16

    • Clinical Trials | Drug Development | Drug Discovery | R&D

      Are We There Yet?

      Many promising cancer treatments are on the horizon
      Adele Graham-King, Contributing Editor 07.14.15


    • APIs | Bioassay Development | Drug Development | Methods Development | Process Development | Toxicology

      The Last Chance Saloon?

      Looking at the pharmaceutical ‘diet’ of anti-obesity drugs
      Adele Graham-King, Contributing Editor 06.02.15

    • Clinical Trials | Drug Development

      100 New Drugs in 10 Years?

      Repurposing drug candidates that never saw the light of day
      Adele Graham-King, Contributing Editor 03.06.15

    • APIs | Bioassay Development | Clinical Trials | Drug Development | Drug Discovery | Methods Development | Process Development | R&D | Toxicology

      Experimental Drugs

      To use or not to use unlicensed drugs? That is the question.
      Adele Graham-King, Contributing Editor 01.29.15


    • Drug Delivery | Drug Development
      The End of a Century

      The End of a Century

      Looking at 15 years of pharmaceutical evolution.
      Adele Graham-King 10.14.14

    • Bioassay Development | Drug Development | Methods Development | Process Development | Toxicology

      A Questionable Combination

      ...
      Ed Silverman, Contributing Editor 06.05.13

    • R&D

      New Jersey Be-Deviled

      A budget cut threatens a biotech initiative
      Ed Silverman 07.09.10

    Trending
    • Bormioli Opens New Glass Research Center
    • Arcline Investment Acquires ChargePoint Technology
    • Spark Therapeutics Appoints CTO
    • The Future Of Vaccines And Biologics
    • BMS Expands Cell Therapy Manufacturing Capabilities
    Breaking News
    • J&J’s Single-Dose COVID-19 Vax Issued EUA
    • Icon to Acquire PRA Health Sciences
    • Phlow Corp. and USP Form Alliance
    • BMS Expands Cell Therapy Manufacturing Capabilities
    • Novo Nordisk Invests $80M in Tablet Production
    View Breaking News >
    CURRENT ISSUE

    January/February 2021

    • High Drug Loading Amorphous Solid Dispersions
    • Parenteral Drug Delivery Trends
    • Selecting the Right Outsourcing Model for Emerging Biotech
    • Inhaled Drug Delivery Technology
    • The Future of Biologics: Accelerating Production, Reducing Costs
    • Business Intelligence For (and From) the Lab
    • Communicating Your Contracting Priorities to Your Drug Company Customers
    • COVID-19 Impact Report
    • The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Martin Bauer Group Acquires Majority Stake in Beverage Company Power Brands
    Gencor Announces Positive Results in VeriSperse Bioavailability Study
    PanTheryx Inc. Acquires TruBiotics Brand from Bayer HealthCare LLC
    Coatings World

    Latest Breaking News From Coatings World

    Gelest CEO Elected to National Academy of Engineering
    PPG Appoints Tony Wu as VP, Automotive Refinish, Asia
    PPG Appoints John Bruno as VP, Investor Relations
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Axonics Buys Contura to Expand to Stress Urinary Incontinence
    Nurx Appoints Chief Medical Officer
    Median Technologies, UC San Diego to Partner on AI-Based Medical Imaging Technology
    Contract Pharma

    Latest Breaking News From Contract Pharma

    J&J’s Single-Dose COVID-19 Vax Issued EUA
    Icon to Acquire PRA Health Sciences
    Phlow Corp. and USP Form Alliance
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Universal Engraving Announces New President
    Raw Sugar Living Expands to Target with New Collection
    Supporting Female Beauty Brand Founders on International Women's Day
    Happi

    Latest Breaking News From Happi

    ACI and CBC Launch Webpage About ‘Quats’
    L’Occitane Launches Hand Cream Inspired by Women
    Kiehl’s Partners with Gyrl Wonder
    Ink World

    Latest Breaking News From Ink World

    Access Direct Mail Doubles Revenue with SCREEN's Truepress Jet520HD
    Etiflex Enters New Markets with Nilpeter FA-22 Installation
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    TLMI analyzes pandemic's effect on label industry in new report
    UEI names Ross Hutchison president
    Schreiner MediPharm and AARDEX partner for clinical trials
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    U.S. Nonwovens Rebrands as Radienz Living
    What You’re Reading on Nonwovens-Industry.com
    Texas Medical Technology Partners with My Protect Kit
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Pandemic Pain: NuVasive's 2020 Sales Fall 10 Percent
    Fusion Robotics Receives FDA Clearance for Spinal Navigation and Robotics System
    Kaia Health Unveils Next-Gen Complete MSK Care Solutions
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027
    Global Smart Glass Market to Register 6.8% CAGR Between 2021-28: Grand View Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login